Point of Care Lipid Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Consumables), By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others), By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others), By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others), By Region and Competition, 2020-2030F
Market Overview
The Global Point of Care Lipid Test Market was valued at USD 735.61 Million in 2024 and is projected to reach USD 1072.48 Million by 2030, registering a CAGR of 6.46%. The market is expanding steadily, driven by the rising incidence of cardiovascular diseases and the growing importance of early lipid level detection. Point-of-care (POC) lipid testing offers rapid, accurate diagnostics, supporting timely clinical decisions in primary care and emergency settings. Increasing health awareness and emphasis on preventive care have accelerated the adoption of POC lipid tests, which are gaining popularity among both physicians and patients for their ease of use and diagnostic value. Their integration into mobile clinics and community pharmacies further enhances accessibility. Advancements in portable lipid analyzers with Bluetooth and cloud capabilities are also transforming patient monitoring and data integration with electronic health records. The demand for multi-analyte platforms that test for multiple biomarkers simultaneously is on the rise, complementing the shift toward decentralized diagnostics and value-based healthcare delivery.
Key Market Drivers
Rising Prevalence of Cardiovascular Diseases and Dyslipidemia
The increasing global burden of cardiovascular diseases (CVDs) and dyslipidemia is a primary driver of the Point of Care (POC) Lipid Test Market. Conditions such as coronary artery disease, hypertension, and stroke remain among the leading causes of death. Dyslipidemia, defined by abnormal cholesterol or triglyceride levels, is a major risk factor. In 2020, nearly 12% of U.S. adults had high total cholesterol, with over 38% displaying borderline or elevated levels. POC lipid testing allows for immediate results, enabling prompt therapeutic actions like prescribing statins or initiating lifestyle interventions. These tests are especially beneficial in primary care, outpatient clinics, and community screenings, helping improve patient compliance and supporting proactive cardiovascular risk management. Public health campaigns have also incorporated POC lipid testing, particularly in rural and underserved areas.
Key Market Challenges
Concerns Regarding Accuracy and Reliability
A notable challenge for the POC lipid test market is the ongoing concern over test accuracy and reliability compared to laboratory-based diagnostics. While the convenience and speed of POC tests are appealing, variability in calibration, operator handling, and environmental conditions can compromise test performance. These inconsistencies may lead to incorrect readings, influencing clinical decisions and potentially affecting patient safety. The diagnostic accuracy of some devices remains under scrutiny, particularly in uncontrolled environments, creating hesitation among clinicians and regulatory bodies. The lack of standardized manufacturing practices and rigorous quality validation also impacts market confidence. In lower-resource settings, insufficient training and infrastructure further limit the reliability of test outcomes. Addressing these concerns will require standardized quality benchmarks, broader training programs, and enhanced device design to match lab-grade diagnostic standards.
Key Market Trends
Integration of Digital Health Technologies
The market is undergoing a digital transformation as point-of-care lipid testing devices increasingly integrate with digital health technologies. These devices now feature real-time data transfer capabilities to electronic health records (EHRs), enhancing clinical decision-making and workflow efficiency. Cloud-based systems support centralized data storage, remote access, and predictive analytics, enabling proactive risk management. Smartphone-compatible devices and mobile health applications allow patients to track cholesterol levels, medication adherence, and lifestyle habits from home, fostering a more engaged and personalized approach to lipid management. Artificial intelligence (AI) and machine learning (ML) tools are also being introduced to interpret test data more accurately and identify complex risk patterns. These innovations align with value-based care strategies and are particularly valuable in supporting long-term disease prevention and management.
Key Market Players
In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market.
Available Customizations
Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The Global Point of Care Lipid Test Market was valued at USD 735.61 Million in 2024 and is projected to reach USD 1072.48 Million by 2030, registering a CAGR of 6.46%. The market is expanding steadily, driven by the rising incidence of cardiovascular diseases and the growing importance of early lipid level detection. Point-of-care (POC) lipid testing offers rapid, accurate diagnostics, supporting timely clinical decisions in primary care and emergency settings. Increasing health awareness and emphasis on preventive care have accelerated the adoption of POC lipid tests, which are gaining popularity among both physicians and patients for their ease of use and diagnostic value. Their integration into mobile clinics and community pharmacies further enhances accessibility. Advancements in portable lipid analyzers with Bluetooth and cloud capabilities are also transforming patient monitoring and data integration with electronic health records. The demand for multi-analyte platforms that test for multiple biomarkers simultaneously is on the rise, complementing the shift toward decentralized diagnostics and value-based healthcare delivery.
Key Market Drivers
Rising Prevalence of Cardiovascular Diseases and Dyslipidemia
The increasing global burden of cardiovascular diseases (CVDs) and dyslipidemia is a primary driver of the Point of Care (POC) Lipid Test Market. Conditions such as coronary artery disease, hypertension, and stroke remain among the leading causes of death. Dyslipidemia, defined by abnormal cholesterol or triglyceride levels, is a major risk factor. In 2020, nearly 12% of U.S. adults had high total cholesterol, with over 38% displaying borderline or elevated levels. POC lipid testing allows for immediate results, enabling prompt therapeutic actions like prescribing statins or initiating lifestyle interventions. These tests are especially beneficial in primary care, outpatient clinics, and community screenings, helping improve patient compliance and supporting proactive cardiovascular risk management. Public health campaigns have also incorporated POC lipid testing, particularly in rural and underserved areas.
Key Market Challenges
Concerns Regarding Accuracy and Reliability
A notable challenge for the POC lipid test market is the ongoing concern over test accuracy and reliability compared to laboratory-based diagnostics. While the convenience and speed of POC tests are appealing, variability in calibration, operator handling, and environmental conditions can compromise test performance. These inconsistencies may lead to incorrect readings, influencing clinical decisions and potentially affecting patient safety. The diagnostic accuracy of some devices remains under scrutiny, particularly in uncontrolled environments, creating hesitation among clinicians and regulatory bodies. The lack of standardized manufacturing practices and rigorous quality validation also impacts market confidence. In lower-resource settings, insufficient training and infrastructure further limit the reliability of test outcomes. Addressing these concerns will require standardized quality benchmarks, broader training programs, and enhanced device design to match lab-grade diagnostic standards.
Key Market Trends
Integration of Digital Health Technologies
The market is undergoing a digital transformation as point-of-care lipid testing devices increasingly integrate with digital health technologies. These devices now feature real-time data transfer capabilities to electronic health records (EHRs), enhancing clinical decision-making and workflow efficiency. Cloud-based systems support centralized data storage, remote access, and predictive analytics, enabling proactive risk management. Smartphone-compatible devices and mobile health applications allow patients to track cholesterol levels, medication adherence, and lifestyle habits from home, fostering a more engaged and personalized approach to lipid management. Artificial intelligence (AI) and machine learning (ML) tools are also being introduced to interpret test data more accurately and identify complex risk patterns. These innovations align with value-based care strategies and are particularly valuable in supporting long-term disease prevention and management.
Key Market Players
- Callegari Srl
- Sinocare Inc.
- Abbott Laboratories
- MiCoBio
- Nova Biomedical
- VivaChek Biotech (Hangzhou) Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Menarini Group
- SD Biosensor, Inc.
- Becton, Dickinson and Company
In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Point of Care Lipid Test Market, By Product:
- Instruments
- Consumables
- Point of Care Lipid Test Market, By Application:
- Hyperlipidemia
- Hypertriglyceridemia
- Tangier Disease
- Hyperlipoproteinemia
- Familial Hypercholesterolemia
- Others
- Point of Care Lipid Test Market, By Disease Indication:
- Lipid and Lipoprotein Disorders
- Atherosclerosis
- Liver and Renal Diseases
- Diabetes Mellitus
- Others
- Point of Care Lipid Test Market, By End User:
- Hospitals
- Clinics
- Research and Diagnostic Laboratories
- Others
- Point of Care Lipid Test Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market.
Available Customizations
Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. GLOBAL POINT OF CARE LIPID TEST MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Instruments, Consumables)
5.2.2. By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)
5.2.3. By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)
5.2.4. By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)
5.2.5. By Company (2024)
5.2.6. By Region
5.3. Market Map
6. NORTH AMERICA POINT OF CARE LIPID TEST MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Disease Indication
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Point of Care Lipid Test Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Disease Indication
6.3.1.2.4. By End User
6.3.2. Mexico Point of Care Lipid Test Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Disease Indication
6.3.2.2.4. By End User
6.3.3. Canada Point of Care Lipid Test Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Disease Indication
6.3.3.2.4. By End User
7. EUROPE POINT OF CARE LIPID TEST MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Disease Indication
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Point of Care Lipid Test Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Disease Indication
7.3.1.2.4. By End User
7.3.2. Germany Point of Care Lipid Test Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Disease Indication
7.3.2.2.4. By End User
7.3.3. United Kingdom Point of Care Lipid Test Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Disease Indication
7.3.3.2.4. By End User
7.3.4. Italy Point of Care Lipid Test Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Disease Indication
7.3.4.2.4. By End User
7.3.5. Spain Point of Care Lipid Test Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Disease Indication
7.3.5.2.4. By End User
8. ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Disease Indication
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Point of Care Lipid Test Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Disease Indication
8.3.1.2.4. By End User
8.3.2. India Point of Care Lipid Test Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Disease Indication
8.3.2.2.4. By End User
8.3.3. South Korea Point of Care Lipid Test Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Disease Indication
8.3.3.2.4. By End User
8.3.4. Japan Point of Care Lipid Test Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Disease Indication
8.3.4.2.4. By End User
8.3.5. Australia Point of Care Lipid Test Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Disease Indication
8.3.5.2.4. By End User
9. SOUTH AMERICA POINT OF CARE LIPID TEST MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Disease Indication
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Point of Care Lipid Test Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Disease Indication
9.3.1.2.4. By End User
9.3.2. Argentina Point of Care Lipid Test Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Disease Indication
9.3.2.2.4. By End User
9.3.3. Colombia Point of Care Lipid Test Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Disease Indication
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA POINT OF CARE LIPID TEST MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Disease Indication
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Point of Care Lipid Test Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Disease Indication
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Point of Care Lipid Test Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Disease Indication
10.3.2.2.4. By End User
10.3.3. UAE Point of Care Lipid Test Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Disease Indication
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. DISRUPTIONS: CONFLICTS, PANDEMICS AND TRADE BARRIERS
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Callegari Srl
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Sinocare Inc.
15.3. Abbott Laboratories
15.4. MiCoBio
15.5. Nova Biomedical
15.6. VivaChek Biotech (Hangzhou) Co., Ltd.
15.7. F. Hoffmann-La Roche Ltd.
15.8. Menarini Group
15.9. SD Biosensor, Inc.
15.10. Becton, Dickinson and Company
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. GLOBAL POINT OF CARE LIPID TEST MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Instruments, Consumables)
5.2.2. By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)
5.2.3. By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)
5.2.4. By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)
5.2.5. By Company (2024)
5.2.6. By Region
5.3. Market Map
6. NORTH AMERICA POINT OF CARE LIPID TEST MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Application
6.2.3. By Disease Indication
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Point of Care Lipid Test Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Application
6.3.1.2.3. By Disease Indication
6.3.1.2.4. By End User
6.3.2. Mexico Point of Care Lipid Test Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Application
6.3.2.2.3. By Disease Indication
6.3.2.2.4. By End User
6.3.3. Canada Point of Care Lipid Test Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Application
6.3.3.2.3. By Disease Indication
6.3.3.2.4. By End User
7. EUROPE POINT OF CARE LIPID TEST MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Application
7.2.3. By Disease Indication
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Point of Care Lipid Test Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Application
7.3.1.2.3. By Disease Indication
7.3.1.2.4. By End User
7.3.2. Germany Point of Care Lipid Test Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Application
7.3.2.2.3. By Disease Indication
7.3.2.2.4. By End User
7.3.3. United Kingdom Point of Care Lipid Test Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Application
7.3.3.2.3. By Disease Indication
7.3.3.2.4. By End User
7.3.4. Italy Point of Care Lipid Test Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Application
7.3.4.2.3. By Disease Indication
7.3.4.2.4. By End User
7.3.5. Spain Point of Care Lipid Test Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Application
7.3.5.2.3. By Disease Indication
7.3.5.2.4. By End User
8. ASIA-PACIFIC POINT OF CARE LIPID TEST MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Application
8.2.3. By Disease Indication
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Point of Care Lipid Test Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Application
8.3.1.2.3. By Disease Indication
8.3.1.2.4. By End User
8.3.2. India Point of Care Lipid Test Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Application
8.3.2.2.3. By Disease Indication
8.3.2.2.4. By End User
8.3.3. South Korea Point of Care Lipid Test Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Application
8.3.3.2.3. By Disease Indication
8.3.3.2.4. By End User
8.3.4. Japan Point of Care Lipid Test Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Application
8.3.4.2.3. By Disease Indication
8.3.4.2.4. By End User
8.3.5. Australia Point of Care Lipid Test Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Application
8.3.5.2.3. By Disease Indication
8.3.5.2.4. By End User
9. SOUTH AMERICA POINT OF CARE LIPID TEST MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Application
9.2.3. By Disease Indication
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Point of Care Lipid Test Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Application
9.3.1.2.3. By Disease Indication
9.3.1.2.4. By End User
9.3.2. Argentina Point of Care Lipid Test Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Application
9.3.2.2.3. By Disease Indication
9.3.2.2.4. By End User
9.3.3. Colombia Point of Care Lipid Test Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Application
9.3.3.2.3. By Disease Indication
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA POINT OF CARE LIPID TEST MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Application
10.2.3. By Disease Indication
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Point of Care Lipid Test Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Application
10.3.1.2.3. By Disease Indication
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Point of Care Lipid Test Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Application
10.3.2.2.3. By Disease Indication
10.3.2.2.4. By End User
10.3.3. UAE Point of Care Lipid Test Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Application
10.3.3.2.3. By Disease Indication
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. DISRUPTIONS: CONFLICTS, PANDEMICS AND TRADE BARRIERS
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Callegari Srl
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Sinocare Inc.
15.3. Abbott Laboratories
15.4. MiCoBio
15.5. Nova Biomedical
15.6. VivaChek Biotech (Hangzhou) Co., Ltd.
15.7. F. Hoffmann-La Roche Ltd.
15.8. Menarini Group
15.9. SD Biosensor, Inc.
15.10. Becton, Dickinson and Company
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
